Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis

BACKGROUND: The optimal first-line immune checkpoint inhibitor (ICI) treatment strategy for metastatic or early triple-negative breast cancer (TNBC) has not yet been determined as a result of various randomized controlled trials (RCTs). The purpose of this study was to compare the efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xueyan, Chen, Xiaoyu, Li, Huijuan, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204114/
https://www.ncbi.nlm.nih.gov/pubmed/37229447
http://dx.doi.org/10.3389/fendo.2023.1137464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204114/
https://www.ncbi.nlm.nih.gov/pubmed/37229447
http://dx.doi.org/10.3389/fendo.2023.1137464

Ejemplares similares